External Advisory Group.
DR. IBRAHIM JALO DAUDU
Chairman, Board of Trustees
Toxinology Society of Nigeria
Former Permanent Secretary in Abuja, Nigeria; Former Head of Service for Governor of Gombe State, Nigeria; Former Director of Administration in the office of the special assistant to the President on Millennium Development Goals; Medical doctor by profession.
Head, Division of Vector
Borne and NTDs
Ministry of Health, Kenya
Former program pharmacist at the national Neglected Tropical Diseases (NTD) Program in 2014 and rapidly rose through the ranks to become the Head, Division of Vector Borne and Neglected Tropical Diseases (DVBNTD) in early 2019. Member of the National Executive Committee of the Pharmaceutical Society of Kenya (PSK), the global Soil-Transmitted Helminthiasis (STH) Advisory Committee, the Global Schistosomiasis Alliance (GSA) and the STH coalition. Chairs the Leishmaniasis East Africa Platform (LEAP) Advisory Committee and is a board member of the Kenya Red Cross Society. Holds a Masters’ Degree in Clinical Pharmacy from the University of Nairobi.
Executive VP & Head of R&D Lava Therapeutics BV
Recognized antibody drug innovator and developer; Inventor of the approved therapeutic antibodies ofatumumab (Arzerra) and daratumumab (DARZALEX) and the clinically translated technologies DuoBody and HexaBody; Previously, Head of Preclinical Development and Research at Genmab (2002-2017); Professor of Molecular Immunology at the Leiden University Medical Center in Leiden, the Netherlands; Board member of The Antibody Society; Former Associate Professor at The Scripps Research Institute in La Jolla, California.
DR. THOMAS KARIUKI
African Academy of Science
Leads Alliance for Accelerating Excellence in Science in Africa (AESA Platform), launched in 2015; Oversees the funding of research, development and commercialisation of novel, high impact STI solutions for the continent; Former Director of the Institute of Primate Research/National Museums of Kenya; Published widely on vaccines/diagnostics development for infectious diseases including schistosomiasis (Bilharzia), malaria and co-infections, and on policy related to biomedical research and funding.
Deputy Director, Clinical Affairs at MassBiologics of the University of Massachusetts Medical School with responsibility for clinical trial design, execution and analysis of multiple phase 1 trials and human proof of concept studies evaluating monoclonal antibodies (mAbs) targeting Clostridium difficile, hepatitis C and rabies. Two mAbs successfully out-licensed for late stage development and regulatory approval; currently on the market as Zinplava (Merck & Co, Inc.) and Rabishield (Serum Institute of India, Pvt. Ltd). Most recently, Vice President Scientific and Clinical Affairs at ClearPath Vaccines overseeing collaboration/execution of IND-enabling antibody assays and animal studies and preparation of clinical regulatory development plan for an innovative vaccine targeting healthcare-associated bacterial pathogens.
Office of the President, Ghana